---
title: "Monte Rosa publishes corporate presentation on targeted protein degradation pipeline and molecular glue degraders"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295098744.md"
description: "Monte Rosa Therapeutics published a corporate presentation detailing its targeted protein degradation pipeline. The company highlighted three clinical molecular glue degrader programs with Phase 2 trials starting in 2026 for immunology, inflammation, and oncology. Key updates include over 90% VAV1 degradation for MRT-6160, 80-90% NEK7 degradation for MRT-8102, and a 100% PSA response rate for MRT-2359. Additionally, Monte Rosa guided its cash runway into 2029, citing $350 million in collaboration payments."
datetime: "2026-08-06T11:25:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295098744.md)
  - [en](https://longbridge.com/en/news/295098744.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295098744.md)
generator: "portal-rs"
---

# Monte Rosa publishes corporate presentation on targeted protein degradation pipeline and molecular glue degraders

-   Monte Rosa highlighted three clinical molecular glue degrader programs with Phase 2 trials starting in 2026 across immunology, inflammation, and oncology. \* Novartis-led MRT-6160 (DDY391) showed over 90% VAV1 degradation in Phase 1; a Phase 2a/b Sjögren’s study is active. \* MRT-8102 interim Phase 1 data showed about 80-90% NEK7 degradation; Phase 2 starts in H2 2026 for elevated atherosclerotic risk. \* MRT-2359 combination data in AR-mutant mCRPC included a 100% PSA response rate; Phase 2 MODeFIRe-1 starts in 3Q 2026. \* Cash runway guided into 2029; collaboration payments totaled about $350 million in three years with potential for over $400 million in 24 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [GLUE.US](https://longbridge.com/en/quote/GLUE.US.md)
- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [NOT.DE](https://longbridge.com/en/quote/NOT.DE.md)

## Related News & Research

- [Monte Rosa doses first patient in Phase 2 MODeFIRe-1 trial of MRT-2359 plus apalutamide in mCRPC](https://longbridge.com/en/news/296776784.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)
- [Gentian Diagnostics hosts webinar on circulating calprotectin use in rheumatic disease management](https://longbridge.com/en/news/296439040.md)
- [11:39 ETJiMMYBAR! Expands into Sam's Club with Nationwide Online Availability and California Club Rollout](https://longbridge.com/en/news/296377299.md)
- [Tiziana Life Sciences launches Phase 2a BANYAN trial of intranasal foralumab in ALS](https://longbridge.com/en/news/296776352.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**